FBLG

0.705015.06%
HK

Hamid Khoja

Chief Scientific Officer

Dr. Hamid Khoja, Ph. D. is Chief Scientific Officer of FibroBiologics, Inc. (Formerly, FibroBiologics LLC) since August 2021. Dr. Khoja provided long-term strategic applications proposals to the CEO, managed external collaborations for product and applications development, assessed new technologies for acquisition and OEM opportunities and presented posters and presentations at numerous scientific conferences. Dr. Khoja led the effort in successfully incorporating Covaris technology into the Illumina Next Generation Sequencing technology protocols leading to over 15000+ citations. Dr. Khoja also developed the Covaris chromatin immunoprecipitation methodology with 3000+ citations in peer reviewed publications, as well as leading the effort in using Covaris technology for simplifying epigenetics assay workflows for use in drug development/discovery and clinical use. Dr. Khoja also led collaborations with NCI for successful development of microbiome DNA extraction using acoustics and completion of FDA EUA SARA-CoC-2 bridge study design for approval of new sample collection and viral RNA extraction using Covaris technology. Dr. Khoja also developed a patented workflow for the manufacturing of synthetic cell-free DNA for use as reference standard in sequencing based liquid biopsy clinical oncology-based assays. In his role at Genomic Solutions, a startup scientific tools company later acquired by Harvard Apparatus, Dr. Khoja led the development of a high throughput protein crystallization platform used in pharmaceutical industry for drug development, managed the scientific applications group, presented company resources at scientific meetings and assessed new technologies for acquisition and OEM opportunities. At the startup phase of Sequenom, Dr. Khoja established the methodology for highly multiplexed PCR used in the development of Sequenom’s massEXTEND technology for MALDI-TOF MS based analysis of single nucleotide polymorphisms and genetic disease. Dr. Khoja led the effort in developing diagnostic MS based assays for hemochromatosis, cystic fibrosis and ten predominantly Jewish genetic diseases using Sequenom’s massEXTEND technology which were then transferred to a large clinical diagnostic company. During his career at Eli Lilly, Dr. Khoja established a high throughput PCR and sequencing strategy using a variety of sequencing strategies and bioinformatic tools available in 1999 for obtaining high coverage genome sequencing which led to the finalizing the first ever complete sequence of the S. pneumoniae genome. At Chiron Corporation, subsequently acquired by Novartis, Dr. Khoja helped in the design, development and optimization of HTP binding assays for FGFR, VEGF, PDGF and EPO receptors, identification of novel g-protein coupled seven transmembrane receptors and identification of novel proteins involved in the TNF signaling pathway and development of branched-DNA based HTP screening for ligand-induced oncogene quantification. Dr. Khoja received his Bachelor of Science in Molecular Biology from the University of Southern California and his Ph. D. in Molecular Biology from Boston University. Dr. Khoja also previously worked at Eli Lilly and Company from November 1998 to September 1999 and Chiron Corporation from October 1995 to October 1998.

Positions